Directors’ / PDMR Dealing
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that it has received notice to exercise options from James Barder, CEO and Ken James, executive Head of R&D to exercise 500,000 options over ordinary shares of 0.2 pence in the Company ("Ordinary Shares").
The following options have been exercised:
| Director | Number of Options exercised | Status | Exercise price | Total number of Options held following exercise |
|---|---|---|---|---|
| James Barder | 250,000 | Unapproved | 30.50p | |
| James Barder | 50,000 | EMI | 15.50p | 3,660,927 |
| Ken James | 200,000 | EMI | 30.50p | 3,455,955 |
James Barder has sold 250,000 Ordinary Shares the proceeds of which will be used to satisfy the tax liability and the exercise of 50,000 options with an exercise price of 15.50p, these shares will be retained by James. In addition, Ken James has sold 200,000 Ordinary Shares.
Following these transactions James Barder's interests in Ordinary Shares is 1,470,972 Ordinary Shares, representing approximately 0.5% of the Company's issued share capital. Ken James' interests in Ordinary Shares of 299,581 Ordinary Shares representing approximately 0.1% of the Company's issued share capital remains unchanged.
450,000 options with an exercise price of 30.50p would lapse on 30 September 2024, if not exercised.
Further disclosures are contained in the tables below.
Total Voting Rights
Following the issue of 500,000 Ordinary Shares under the Company's existing block listings to satisfy the exercise of options, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 302,363,641 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 302,363,641 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
| a) | Name | James Barder |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | 1. Exercise of options with exercise price of 30.50p 2. Disposal of 250,000 ordinary shares following exercise 3. Exercise of 50,000 options with exercise price of 15.50p |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 1. 30.50p 250,000 2. 40.6628p 250,000 3. 15.50p 50,000 |
| d) | Aggregated information - Aggregated volume - Price | 1. 250,000 2. 250,000 3. 65,000 1. £76,250.00 2. £101,657.00 3. £7,750 |
| e) | Date of the transaction | 12 September 24 |
| f) | Place of the transaction | 1. Outside a trading venue 2. XLON 3. Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Ken James |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Director and Head of R&D |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | 1. Exercise of options with exercise price of 30.50p 2. Disposal of 200,000 ordinary shares following exercise |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 1. 30.50p 200,000 2. 40.6628p 200,000 |
| d) | Aggregated information - Aggregated volume - Price | 1. 200,000 2. 200,000 1. £61,000.00 2. £81,325.60 |
| e) | Date of the transaction | 12 September 2024 |
| f) | Place of the transaction | 1. Outside a trading venue 2. XLON |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.